Prostate Cancer, Version 2.2014
James L. Mohler, Maria Ho, Eric J. Small(CancerCare Manitoba), Michael B. Cohen(Albany Medical Center Hospital), Edward M. Schaeffer(Northwestern University), Christopher J. Kane(University of California San Diego), Elizabeth R. Plimack(Fox Chase Cancer Center), Eric Rohren(Society of Nuclear Medicine and Molecular Imaging), Andrew J. Armstrong(Duke University), Richard J. Lee(La Roche College), Jonathan D. Tward(University of Utah), Julio M. Pow‐Sang(Moffitt Cancer Center), Sylvia Richey(St. Jude Children's Research Hospital), Seth A. Strope(Barnes-Jewish Hospital), Eric M. Horwitz(Fox Chase Cancer Center), Guru Sonpavde(AdventHealth Orlando), Philip W. Kantoff(Convergent Science (United States)), Anthony V. D’Amico(Brigham and Women's Hospital), Dorothy A. Shead(University of the Witwatersrand), David Raben(St. Jude Children's Research Hospital), Stan Rosenfeld(Office of Patient Care Services), Mack Roach(University of California, San Francisco), David C. Miller(University of Michigan), Thomas A. Farrington(Health Net), Sandy Srinivas(Stanford University), Arnold W. Malcolm(Vanderbilt University), Cy A. Stein(City Of Hope National Medical Center), Charles A. Enke(Susan Thompson Buffett Foundation), Robert R. Bahnson(Fox Chase Cancer Center), Michael Kuettel, Mark H. Kawachi(City of Hope), Celestia S. Higano(University of British Columbia), James A. Eastham(Memorial Sloan Kettering Cancer Center), Timothy M. Kuzel(Rush University)
Cited by 334
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k